Most costly trial amendments stem from avoidable human errors in setting patient eligibility parameters. Large language models can systematically flag overly restrictive inclusion criteria or overly broad exclusion criteria during early draft stages before studies encounter regulatory pushback.
AI software represents a costly operational risk if vendors cannot explain how their underlying models arrive at specific conclusions. Sponsors and CROs must push beyond demonstrations to ensure vendor systems can cite grounded rationale before deployment in regulated workflows.
Life sciences AI vendors can satisfy regulatory demands for explainability without exposing proprietary model code. By providing empirical rationale—such as matching past cohort sizes from similar indications—platforms ground recommendations while protecting their intellectual property.
Models trained indiscriminately on historical trials risk reproducing outdated practices and bias. Instead of mimicking historical trial designs directly, systems must dissect what specific flaws triggered past protocol amendments so the algorithm learns what to avoid.
AI models cannot replace clinical investigators; instead, they function as drafting tools that produce high-quality initial baselines. Pairing automated generation with expert clinical validation allows development teams to reach 86% submission-ready protocol drafts while meeting stringent FDA and EMA standards.
Rapid trial generation is counterproductive if accelerated drafts lack scientific rigor and regulatory precision. Teams adopting clinical AI must strike an optimal balance between reducing generation timelines and maintaining the strict quality required to pass regulatory scrutiny.